- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07585669
Effects of Omega-3 Fatty Acids on Inflammation and Gut Microbiota in Celiac Disease (OMEGA-CD)
Modulation of Blood and Small Intestinal Inflammatory Processes and Fecal Microbiota in Celiac Disease Associated With the Intake of n-3 Polyunsaturated Fatty Acids
The goal of this clinical trial is to learn if omega-3 fatty acid supplements (n-3 PUFAs) can help reduce inflammation and promote intestinal healing in adults newly diagnosed with celiac disease (CD).
Celiac disease is a chronic autoimmune disorder where eating gluten-a protein found in wheat-triggers an immune response that damages the lining of the small intestine. This damage causes inflammation and symptoms such as stomach pain, diarrhea, and nutrient absorption problems. The only current treatment is a strict gluten-free diet (GFD), which can help most people recover, but some continue to have inflammation and symptoms.
This study will test whether supplementing with 2.4 grams of n-3 PUFAs daily for three months, alongside starting a gluten-free diet, reduces inflammation in the blood and intestine more effectively than the gluten-free diet alone.
Participants will:
Be adults recently diagnosed with celiac disease who have not yet started a gluten-free diet
Be randomly assigned to one of two groups:
One group will receive omega-3 supplements containing 2,400 mg of n-3 PUFAs daily (2,000 mg DHA and 400 mg EPA) The other group will receive a placebo (a pill with no active ingredients that looks like the supplement) Take the assigned supplement every day for 3 months while following a supervised gluten-free diet Visit the clinic regularly for checkups, blood tests, and monitoring of symptoms and diet adherence Provide blood and stool samples before and after the intervention to measure inflammation and changes in gut bacteria A subgroup of participants will undergo small intestinal biopsies to assess local inflammation and healing
The study aims to answer these main questions:
Does omega-3 supplementation change the fatty acid composition in blood cells? Does it reduce markers of inflammation in the blood and small intestine? Does it improve the diversity and health of gut bacteria in the intestine? Does it help the small intestine heal faster compared to diet alone?
Researchers will measure inflammation by analyzing immune signaling pathways, oxidative stress markers, and antioxidant activity in blood cells. They will also study the composition of the gut microbiota and its metabolites. These detailed measurements will help understand how omega-3 fatty acids may influence the immune response and gut health in celiac disease.
This is a randomized, double-blind, placebo-controlled crossover study. This means participants and researchers will not know who receives the supplement or placebo during the study period, reducing bias and improving the reliability of the results.
This study is important because it could offer a simple, additional treatment to improve recovery in celiac disease beyond the gluten-free diet. If omega-3 supplements are shown to reduce inflammation and support healing, they could become a valuable part of managing this chronic condition.
Participation is voluntary, and participants can leave the study at any time without affecting their medical care. All participants will be closely monitored to ensure safety throughout the study.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Karla A Bascuñán, PhD
- Numer telefonu: +56 2 9773232
- E-mail: kbascunan@uchile.cl
Lokalizacje studiów
-
-
Metropolitan Region
-
Santiago, Metropolitan Region, Chile, 8380000
- Rekrutacyjny
- University of Chile Clinical Hospital
-
Kontakt:
- Paulina Toledo (Clinical Research Coordinator)+569
- Numer telefonu: 987299944
- E-mail: ptoledo@hcuchi.cl
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Opis
Inclusion Criteria:
- Adult patients aged 18 to 65 years, Newly diagnosed with celiac disease confirmed by serology and intestinal biopsy, Not yet started gluten-free diet (GFD), Willingness to adhere to a supervised gluten-free diet during the study, Able to provide informed consent
Exclusion Criteria:
- Previous or current adherence to a gluten-free diet, Use of n-3 PUFA supplements or other dietary supplements influencing inflammation within the last 3 months, Presence of other autoimmune, inflammatory, or gastrointestinal diseases (e.g., Crohn's disease, ulcerative colitis), Pregnancy or breastfeeding, Severe chronic illnesses that may interfere with the study or outcomes (e.g., uncontrolled diabetes, cancer), Allergy or intolerance to fish oil or components of the supplement, Use of immunosuppressive or anti-inflammatory medication within the last 3 months
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Zadanie krzyżowe
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Omega-3 PUFA Supplement
Participants in this group will receive daily oral supplementation with 2,400 mg of omega-3 polyunsaturated fatty acids (2,000 mg DHA and 400 mg EPA) for 3 months.
All participants will start a supervised gluten-free diet at the same time.
Clinical symptoms, dietary adherence, and safety will be monitored throughout the intervention period.
|
n-3 PUFAs supplementation consisting of 2,400 mg per day (2,000 mg docosahexaenoic acid [DHA] and 400 mg eicosapentaenoic acid [EPA]), administered orally for 3 months in newly diagnosed adult celiac disease patients.
The supplementation is given alongside the initiation of a gluten-free diet (GFD).
The aim is to assess whether supplementation modulates the inflammatory response and supports intestinal recovery.
This is part of a randomized, double-blind, placebo-controlled, crossover trial comparing supplementation versus placebo.
Inne nazwy:
|
|
Komparator placebo: Placebo
Participants in this group will receive a daily oral placebo supplement, identical in appearance and taste to the omega-3 supplement, for 3 months.
All participants will begin a supervised gluten-free diet at the same time.
Clinical symptoms, dietary adherence, and safety will be monitored throughout the intervention period.
|
Placebo capsules identical in appearance and taste to the active n-3 polyunsaturated fatty acid (PUFA) supplement, administered orally once daily for 3 months in newly diagnosed adult celiac disease patients.
Participants will simultaneously begin a supervised gluten-free diet.
This intervention serves as a control to evaluate the effect of the active supplement on modulating the inflammatory response and intestinal recovery.
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Modulation of systemic inflammatory response via cytokine levels and NF-κB signaling in peripheral blood mononuclear cells
Ramy czasowe: From baseline (T0) to 3 months (T3) of supplementation
|
Levels of proinflammatory cytokines and NF-κB signaling in peripheral blood mononuclear cells will be measured to assess the reduction of systemic inflammation in newly diagnosed adult celiac patients receiving n-3 PUFA supplementation versus placebo.
|
From baseline (T0) to 3 months (T3) of supplementation
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Changes in fatty acid composition of erythrocyte and peripheral blood mononuclear cell membranes
Ramy czasowe: From baseline (T0) to 3 months (T3) of supplementation
|
The fatty acid profiles of erythrocyte and peripheral blood mononuclear cell membranes will be analyzed at baseline and after 3 months to assess the impact of n-3 PUFA supplementation on membrane lipid composition in adult celiac disease patients.
|
From baseline (T0) to 3 months (T3) of supplementation
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Evaluation of intestinal inflammation and microbiota composition in newly diagnosed celiac disease patients following n-3 PUFA supplementation
Ramy czasowe: From baseline (T0) to 3 months post-intervention (T3)
|
Assessment of local intestinal inflammation and gut microbiota changes in newly diagnosed adult celiac disease patients receiving 2.4 g/day of n-3 polyunsaturated fatty acids alongside a supervised gluten-free diet. Intestinal biopsies and fecal samples will be collected at baseline (T0) and after 3 months (T3) to measure inflammatory markers (e.g., NFκB, pro-inflammatory cytokines, I-FABP) and characterize fecal microbiota diversity and short-chain fatty acid profiles. This will determine the impact of n-3 PUFA supplementation on mucosal inflammation and the intestinal microenvironment. Time Frame: |
From baseline (T0) to 3 months post-intervention (T3)
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby metaboliczne
- Choroby jelit
- Choroby Układu Pokarmowego
- Choroby przewodu pokarmowego
- Zespoły złego wchłaniania
- Choroby żywieniowe i metaboliczne
- Nietolerancja glutenu
- Kwasy tłuszczowe
- Lipidy
- Kwasy tłuszczowe, nienasycone
- Obrazy olejne
- Tłuszcze dietetyczne
- Tłuszcze
- Tłuszcze dietetyczne, nienasycone
- Oleje rybne
- Kwasy tłuszczowe, omega-3
Inne numery identyfikacyjne badania
- 11240685
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Nietolerancja glutenu
-
Peking University Third HospitalJeszcze nie rekrutacjaCentral Compartment Atopic Disease (CCAD)Chiny
-
Bambino Gesù Hospital and Research InstituteZakończonyCiężka otyłość dziecięca (BMI > 97° szt. -według wykresów BMI Centers for Disease Control and Prevention-) | Zmienione testy czynnościowe wątroby | Nietolerancja glikemicznaWłochy
-
Spero TherapeuticsZakończonyKompleks Mycobacterium Avium | Niegruźlicze Mycobacterium Pulmonary DiseaseStany Zjednoczone
-
Janssen Pharmaceutical K.K.ZakończonyOporna na leczenie Mycobacterium Avium Complex-lung Disease (MAC-LD)Tajwan, Japonia, Korea Południowa
-
Adelphi Values LLCBlueprint Medicines CorporationZakończonyBiałaczka z komórek tucznych (MCL) | Agresywna mastocytoza układowa (ASM) | SM w Assoc Clonal Hema Lineage Non-mast Cell Lineage Disease (SM-AHNMD) | Tląca się mastocytoza układowa (SSM) | Indolentna układowa mastocytoza (ISM) Podgrupa ISM w pełni zatrudnionaStany Zjednoczone